Gastric squamous cell carcinoma and gastric adenosquamous carcinoma, clinical features and outcomes of rare clinical entities: a National Cancer Database (NCDB) analysis.
Gastric cancer
gastric adenocarcinoma (GAC)
gastric adenosquamous carcinoma (GASC)
gastric squamous cell carcinoma (GSCC)
rare gastric cancers
Journal
Journal of gastrointestinal oncology
ISSN: 2078-6891
Titre abrégé: J Gastrointest Oncol
Pays: China
ID NLM: 101557751
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
entrez:
22
2
2019
pubmed:
23
2
2019
medline:
23
2
2019
Statut:
ppublish
Résumé
Gastric squamous cell carcinoma (GSCC) and gastric adenosquamous carcinoma (GASC) comprise less than 2% of gastric cancers. The current knowledge about clinical presentation, treatment modalities and outcomes of GSCC and GASC is limited. The aim of this study is to characterize the clinicopathological features, treatment modalities, and outcomes of GSCC and GASC in comparison to gastric adenocarcinoma (GAC) in National Cancer Database (NCDB). Patients with GSCC, GASC and GAC between 2004 and 2013 were identified using ICD-O-3 histology and topography codes 8070/3, 8560/3, 8140/3 and C16.0-9. Univariate, and multivariate analysis were performed, and Kaplan-Meier curves was used to compare survival based on histological subtype. A total of 61,215 patients were identified, 836 (1.4%) GSCC, 327 (0.5%) GASC, 60,052 (98.1%) GAC between 2004 and 2013, in which 77.4% was Caucasian and 68.7% was male, 46.6% of tumors were in gastric cardia and 13.7% in gastric antrum. Neoadjuvant and adjuvant chemotherapy was administered in 11.2%, 14.1%, 8.9% GSCC and GASC have poorer survival outcomes compared to GAC. Less patients with GSCC received surgery and adjuvant chemotherapy, more patients with GSCC received radiation therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Gastric squamous cell carcinoma (GSCC) and gastric adenosquamous carcinoma (GASC) comprise less than 2% of gastric cancers. The current knowledge about clinical presentation, treatment modalities and outcomes of GSCC and GASC is limited. The aim of this study is to characterize the clinicopathological features, treatment modalities, and outcomes of GSCC and GASC in comparison to gastric adenocarcinoma (GAC) in National Cancer Database (NCDB).
METHODS
METHODS
Patients with GSCC, GASC and GAC between 2004 and 2013 were identified using ICD-O-3 histology and topography codes 8070/3, 8560/3, 8140/3 and C16.0-9. Univariate, and multivariate analysis were performed, and Kaplan-Meier curves was used to compare survival based on histological subtype.
RESULTS
RESULTS
A total of 61,215 patients were identified, 836 (1.4%) GSCC, 327 (0.5%) GASC, 60,052 (98.1%) GAC between 2004 and 2013, in which 77.4% was Caucasian and 68.7% was male, 46.6% of tumors were in gastric cardia and 13.7% in gastric antrum. Neoadjuvant and adjuvant chemotherapy was administered in 11.2%, 14.1%, 8.9%
CONCLUSIONS
CONCLUSIONS
GSCC and GASC have poorer survival outcomes compared to GAC. Less patients with GSCC received surgery and adjuvant chemotherapy, more patients with GSCC received radiation therapy.
Identifiants
pubmed: 30788163
doi: 10.21037/jgo.2018.10.06
pii: jgo-10-01-85
pmc: PMC6351299
doi:
Types de publication
Journal Article
Langues
eng
Pagination
85-94Subventions
Organisme : NCI NIH HHS
ID : P30 CA138292
Pays : United States
Déclaration de conflit d'intérêts
Conflicts of Interest: The authors have no conflicts of interest to declare.
Références
Gastric Cancer. 1998 Dec;1(1):10-24
pubmed: 11957040
Cancer. 1965 Feb;18:181-92
pubmed: 14254074
Hepatogastroenterology. 2005 May-Jun;52(63):969-74
pubmed: 15966243
J Med Case Rep. 2010 Oct 29;4:351
pubmed: 21034475
Surg Today. 2012 Jul;42(7):666-9
pubmed: 22350299
J Dig Dis. 2012 Aug;13(8):407-13
pubmed: 22788926
Indian J Pathol Microbiol. 2013 Oct-Dec;56(4):416-8
pubmed: 24441236
J Gastric Cancer. 2014 Mar;14(1):58-62
pubmed: 24765539
World J Gastroenterol. 2014 Aug 7;20(29):10193-201
pubmed: 25110448
Oncol Lett. 2014 Nov;8(5):2122-2124
pubmed: 25289093
Pathol Oncol Res. 2015 Jul;21(3):547-51
pubmed: 25567665
World J Surg Oncol. 2015 Apr 02;13:136
pubmed: 25889482
World J Gastroenterol. 2015 Apr 14;21(14):4385-90
pubmed: 25892891
Medicine (Baltimore). 2016 Aug;95(34):e4720
pubmed: 27559983
Abdom Radiol (NY). 2017 Jan;42(1):124-140
pubmed: 27645897
Sci Rep. 2017 Jul 4;7(1):4597
pubmed: 28676632
Medicine (Baltimore). 2017 Dec;96(50):e9224
pubmed: 29390350
Cancer. 1969 Nov;24(5):985-95
pubmed: 5353950
Am J Roentgenol Radium Ther Nucl Med. 1967 Oct;101(2):447-9
pubmed: 6045404
Cancer. 1995 Jan 1;75(1 Suppl):154-70
pubmed: 8000994
Jpn J Clin Oncol. 1996 Aug;26(4):252-7
pubmed: 8765185